Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2025-12-25 @ 9:49 PM
Study NCT ID:
NCT05947851
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2023-07-07
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015451', 'term': 'Leukemia, Lymphocytic, Chronic, B-Cell'}], 'ancestors': [{'id': 'D015448', 'term': 'Leukemia, B-Cell'}, {'id': 'D007945', 'term': 'Leukemia, Lymphoid'}, {'id': 'D007938', 'term': 'Leukemia'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000721068', 'term': 'ARQ531'}, {'id': 'C579720', 'term': 'venetoclax'}, {'id': 'D000069283', 'term': 'Rituximab'}], 'ancestors': [{'id': 'D058846', 'term': 'Antibodies, Monoclonal, Murine-Derived'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'In Part 1, Dose Confirmation will be determined by modified toxicity probability interval (mTPI) design, where participants will be assigned to two treatment groups, Nemtabrutinib + Venetoclax in parallel with Nemtabrutinib + Venetoclax. Part 2 will be an Efficacy Expansion where all participants will be randomized 1:1 to Nemtabrutinib Part 1 Dose Selection plus Venetoclax or Venetoclax plus Rituximab (VR) (or Rituximab biosimilar) for the duration of the study.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 735}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2023-08-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2035-07-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-23', 'studyFirstSubmitDate': '2023-07-07', 'studyFirstSubmitQcDate': '2023-07-07', 'lastUpdatePostDateStruct': {'date': '2025-12-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-07-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2032-06-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)', 'timeFrame': 'Up to approximately 12 Weeks', 'description': 'DLT evaluation period is defined as 8 weeks after the first dose of the combination treatment of nemtabrutinib plus venetoclax Cycle 2 Day 1 in Part 1 + 4 weeks follow up. Each cycle is 4 weeks. DLTs are: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting \\>7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for \\>1 week (with exceptions); missing \\>25% of nemtabrutinib or venetoclax doses as a result of drug-related adverse events during the first 2 cycles; Grade 5 toxicity.'}, {'measure': 'Part 1: Number of Participants Experiencing Adverse Events (AEs)', 'timeFrame': 'Up to approximately 28 months', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1.'}, {'measure': 'Part 1: Number of Participants Discontinuing Study Treatment Due to AEs', 'timeFrame': 'Up to approximately 25 months', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to AEs will be reported for Part 1.'}, {'measure': 'Part 2: PFS per the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria as Assessed by Blinded Independent Central Review (BICR)', 'timeFrame': 'Up to approximately 71 months', 'description': 'PFS is defined as the time from randomization to the first documented disease progression per iwCLL criteria 2018 as accessed by BICR, or death due to any cause, whichever occurs first. PFS will be presented.'}], 'secondaryOutcomes': [{'measure': 'Part 2: Undetectable Minimal Residual Disease (MRD) Rate in Bone Marrow as Assessed by Central Laboratory', 'timeFrame': 'Up to approximately 46 months', 'description': 'Undetectable MRD, defined as \\<1 leukemic cell per 10,000 cells (MRD \\<10-4) in bone marrow. The MRD rate will be presented.'}, {'measure': 'Part 2: Overall Survival (OS)', 'timeFrame': 'Up to approximately 108 months', 'description': 'OS, defined as the time from randomization to death due to any cause. OS will be presented.'}, {'measure': 'Part 2: Objective Response Rate (ORR) per iwCLL Criteria 2018 as Assessed by BICR', 'timeFrame': 'Up to approximately 71 months', 'description': 'OR, defined as complete response/remission (CR), complete response with incomplete count recovery (CRi), nodular partial remission (nPR), or partial remission (PR). CR is defined as meeting the following criteria: no lymph nodes \\>1.5 cm, spleen size \\<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10\\^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10\\^9/L or ≥50% increase from screening, hemoglobin \\>11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. ORR will be presented.'}, {'measure': 'Part 2: Duration of Response (DOR) per iwCLL Criteria 2018 as Assessed by BICR', 'timeFrame': 'Up to approximately 108 months', 'description': 'DOR, defined as the time from the first documented evidence of CR, CRi, nPR, or PR that led to response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes \\>1.5 cm, spleen size \\<13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10\\^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10\\^9/L or ≥50% increase from screening, hemoglobin \\>11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. DOR will be presented.'}, {'measure': 'Part 2: Number of Participants Experiencing AEs', 'timeFrame': 'Up to approximately 28 months', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2.'}, {'measure': 'Part 2: Number of Participants Discontinuing Study Treatment Due to AEs', 'timeFrame': 'Up to approximately 25 months', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to AEs will be reported for Part 2.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Leukemia, Lymphocytic, Chronic, B-Cell', 'Leukemia, Chronic Lymphocytic', 'Small-Cell Lymphoma', 'Lymphoma, Small Lymphocytic', 'CLL', 'SLL']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.merckclinicaltrials.com', 'label': 'Merck Clinical Trials Information'}, {'url': 'https://msd.trialsummaries.com/Study/StudyDetails?id=26318&tenant=MT_MSD_9011', 'label': 'Plain Language Summary'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and active disease clearly documented to initiate therapy\n* Deletion (Del) (17p) status, tumor protein 53 (TP53) mutation status, and immunoglobulin heavy chain gene (IGHV) mutation status results required before randomization for Part 2 participants only\n* Relapsed or refractory to at least 1 prior available therapy\n* Have at least 1 marker of disease burden\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization\n* Has a life expectancy of at least 3 months\n* Has the ability to swallow and retain oral medication\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization\n* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening\n* Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria\n* Participants with adequate organ function with specimens collected within 7 days before the start of study intervention\n* If capable of producing sperm, participant agrees to eliminate Nemtabrutinib: 12 days, Venetoclax: 1 month (30 days), Rituximab (rituximab biosimilar): not applicable; abstains from penile-vaginal intercourse as their preferred and usual lifestyle; OR uses prescribed contraception\n* Participant assigned female sex at birth are eligible to participate if not pregnant or breastfeeding and are not a person of childbearing potential (POCBP) OR is a POCBP and uses a contraceptive method that is highly effective, has a negative highly sensitive pregnancy test, and abstains from breastfeeding\n\nExclusion Criteria:\n\n* Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection\n* Has gastrointestinal (GI) dysfunction that may affect drug absorption\n* Has a known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL\n* Has an active infection requiring systemic therapy, such as intravenous (IV) antibiotics, during screening\n* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease and/or acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening\n* Clinically significant cardiovascular disease\n* Has a known allergy/sensitivity to nemtabrutinib or contraindication to venetoclax/rituximab (or rituximab biosimilar), or any of the excipients\n* Has history of severe bleeding disorders (eg, hemophilia)\n* Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization\n* Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) within ≤ 12 months before randomization or has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids\n* Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors.\n* Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention\n* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration\n* Has a known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications"}, 'identificationModule': {'nctId': 'NCT05947851', 'briefTitle': 'A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).', 'organization': {'class': 'INDUSTRY', 'fullName': 'Merck Sharp & Dohme LLC'}, 'officialTitle': 'A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)', 'orgStudyIdInfo': {'id': '1026-010'}, 'secondaryIdInfos': [{'id': 'MK-1026-010', 'type': 'OTHER', 'domain': 'MSD'}, {'id': 'BELLWAVE-010', 'type': 'OTHER', 'domain': 'MSD'}, {'id': '2022-501560-17-00', 'type': 'REGISTRY', 'domain': 'EU CT'}, {'id': 'U1111-1281-1520', 'type': 'REGISTRY', 'domain': 'UTN'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Nemtabrutinib + Venetoclax', 'description': 'Participants will receive nemtrabrutinib oral tablets at specified doses daily starting at Cycle 1 Day 1 (C1D1) and venetoclax oral tablets at doses of 20 mg up to 400 mg daily starting at Cycle 2 Day 1 (C2D1) up to 2 years post C2D1 or until progressive disease (PD) or discontinuation. A cycle = 4 weeks.', 'interventionNames': ['Drug: Nemtabrutinib', 'Drug: Venetoclax']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Venetoclax + Rituximab', 'description': 'Participants will receive venetoclax oral tablets at doses from 20 mg up to 400 mg daily starting at C1D1 on 4-week cycles up to 2 years and rituximab or biosimilar at 375 mg/m\\^2 up to 500 mg/m2 intravenous infusion once per 28-day cycle starting at C2D1, for 6 total cycles. Treatment will continue until progressive disease (PD) or discontinuation.', 'interventionNames': ['Drug: Venetoclax', 'Biological: Rituximab']}], 'interventions': [{'name': 'Nemtabrutinib', 'type': 'DRUG', 'otherNames': ['ARQ 531', 'MK-1026'], 'description': '5, 20, 45, and 65 mg tablets', 'armGroupLabels': ['Nemtabrutinib + Venetoclax']}, {'name': 'Venetoclax', 'type': 'DRUG', 'otherNames': ['ABT-199', 'GDC-0199'], 'description': '10, 50, and 100 mg tablets', 'armGroupLabels': ['Nemtabrutinib + Venetoclax', 'Venetoclax + Rituximab']}, {'name': 'Rituximab', 'type': 'BIOLOGICAL', 'description': '100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion', 'armGroupLabels': ['Venetoclax + Rituximab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '72762', 'city': 'Springdale', 'state': 'Arkansas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '888-577-8839'}], 'facility': 'Highlands Oncology Group ( Site 5405)', 'geoPoint': {'lat': 36.18674, 'lon': -94.12881}}, {'zip': '90806', 'city': 'Long Beach', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '888-577-8839'}], 'facility': 'MemorialCare Health System - Long Beach Medical Center ( Site 5421)', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'zip': '33028', 'city': 'Pembroke Pines', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '888-577-8839'}], 'facility': 'Memorial Hospital West ( Site 5410)', 'geoPoint': {'lat': 26.00315, 'lon': -80.22394}}, {'zip': '97239-3011', 'city': 'Portland', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '888-577-8839'}], 'facility': 'Oregon Health and Science University ( Site 5425)', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '99208', 'city': 'Spokane', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '888-577-8839'}], 'facility': 'Medical Oncology Associates, PS ( Site 5406)', 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'zip': '53792', 'city': 'Madison', 'state': 'Wisconsin', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '888-577-8839'}], 'facility': 'University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423)', 'geoPoint': {'lat': 43.07305, 'lon': -89.40123}}, {'zip': 'C1426ANZ', 'city': 'Ciudad Autónoma de Buenos Aires', 'state': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+541132218900'}], 'facility': 'Instituto Alexander Fleming ( Site 1005)'}, {'zip': 'B7600FZO', 'city': 'Mar del Plata', 'state': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+542234963224'}], 'facility': 'Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007)', 'geoPoint': {'lat': -38.00042, 'lon': -57.5562}}, {'zip': 'S2000CUB', 'city': 'Rosario', 'state': 'Santa Fe Province', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+543414200222'}], 'facility': 'Sanatorio Parque ( Site 1003)', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': '1414', 'city': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+541148544097'}], 'facility': 'Centro Medico Fleischer ( Site 1006)', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1118AAT', 'city': 'Buenos Aires', 'status': 'RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+541148277000'}], 'facility': 'Hospital Aleman-oncohematologic diseases ( Site 1001)', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '5000', 'city': 'Adelaide', 'state': 'South Australia', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+61870740000'}], 'facility': 'Royal Adelaide Hospital ( Site 1104)', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'zip': '3021', 'city': 'Melbourne', 'state': 'Victoria', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+61383959130'}], 'facility': 'Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103)', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'zip': '3000', 'city': 'Leuven', 'state': 'Vlaams-Brabant', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+32 16/338544'}], 'facility': 'UZ Leuven-Hematology ( Site 1200)', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '2030', 'city': 'Antwerp', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+32 3/339 76 38'}], 'facility': 'ZAS Cadix ( Site 1203)', 'geoPoint': {'lat': 51.22047, 'lon': 4.40026}}, {'zip': '01246-000', 'city': 'São Paulo', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'Brazil', 'facility': 'ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308)', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': 'E1C 6Z8', 'city': 'Moncton', 'state': 'New Brunswick', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '506-870-2404'}], 'facility': 'The Moncton Hospital ( Site 1414)', 'geoPoint': {'lat': 46.09454, 'lon': -64.7965}}, {'zip': '1720430', 'city': 'La Serena', 'state': 'Coquimbo Region', 'status': 'RECRUITING', 'country': 'Chile', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+56958646664'}], 'facility': 'IC La Serena Research ( Site 1506)', 'geoPoint': {'lat': -29.90591, 'lon': -71.25014}}, {'zip': '7500653', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'status': 'RECRUITING', 'country': 'Chile', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+56991612199'}], 'facility': 'Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7500921', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'status': 'RECRUITING', 'country': 'Chile', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '56224205098'}], 'facility': 'FALP-UIDO ( Site 1500)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7580206', 'city': 'Santiago', 'state': 'Region M. de Santiago', 'status': 'RECRUITING', 'country': 'Chile', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+56224376600'}], 'facility': 'Clínica Inmunocel ( Site 1511)', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '4070196', 'city': 'Concepción', 'state': 'Región del Biobío', 'status': 'RECRUITING', 'country': 'Chile', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+56412858421'}], 'facility': 'Biocenter ( Site 1507)', 'geoPoint': {'lat': -36.82699, 'lon': -73.04977}}, {'zip': '760032', 'city': 'Cali', 'state': 'Valle del Cauca Department', 'status': 'RECRUITING', 'country': 'Colombia', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '57 3133288646'}], 'facility': 'Fundación Valle del Lili ( Site 1703)', 'geoPoint': {'lat': 3.43054, 'lon': -76.5199}}, {'zip': '59037', 'city': 'Lille', 'state': 'Nord', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+333 20 44 59 62'}], 'facility': 'Hopital Claude Huriez - CHU de Lille ( Site 2107)', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'zip': '63100', 'city': 'Clermont-Ferrand', 'state': 'Puy-de-Dome', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+33473750065'}], 'facility': 'Centre Hospitalier Universitaire Estaing ( Site 2105)', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'zip': '85925', 'city': 'La Roche-sur-Yon', 'state': 'Vendee', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+33251446572'}], 'facility': 'CHD Vendee ( Site 2100)', 'geoPoint': {'lat': 46.66974, 'lon': -1.42757}}, {'zip': '54290', 'city': 'Trier', 'state': 'Rhineland-Palatinate', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+496519472571'}], 'facility': 'Klinikum Mutterhaus der Borromäerinnen-Innere Medizin I ( Site 2203)', 'geoPoint': {'lat': 49.75565, 'lon': 6.63935}}, {'zip': '04103', 'city': 'Leipzig', 'state': 'Saxony', 'status': 'RECRUITING', 'country': 'Germany', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+49 341 97 13131'}], 'facility': 'Universitätsklinikum Leipzig-Medical Department I - Hematology and Celltherapy ( Site 2201)', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '3109601', 'city': 'Haifa', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+97247771514'}], 'facility': 'Rambam Health Care Campus ( Site 2801)', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '9112001', 'city': 'Jerusalem', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+972-539101736'}], 'facility': 'Hadassah Medical Center-Hemato-Oncology ( Site 2812)', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '5265601', 'city': 'Ramat Gan', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+972-35308401'}], 'facility': 'Sheba Medical Center-Hemato Oncology ( Site 2809)', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'zip': '6423906', 'city': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+97237772649'}], 'facility': 'Sourasky Medical Center ( Site 2811)', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '15121', 'city': 'Alessandria', 'state': 'Ancona', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+390131206440'}], 'facility': 'Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2906)', 'geoPoint': {'lat': 44.90924, 'lon': 8.61007}}, {'zip': '20132', 'city': 'Milan', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+390226436119'}], 'facility': 'Ospedale San Raffaele-Programma di Ricerca Strategica sulla LLC ( Site 2902)', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '42123', 'city': 'Reggio Emilia', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+390522295654'}], 'facility': 'Arcispedale Santa Maria Nuova-Hematology ( Site 2900)', 'geoPoint': {'lat': 44.69825, 'lon': 10.63125}}, {'zip': '03100', 'city': 'Mexico City', 'state': 'Mexico City', 'status': 'RECRUITING', 'country': 'Mexico', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+52 55 5264 6440'}], 'facility': 'Centro de Infusion Superare ( Site 3314)', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '03100', 'city': 'Mexico City', 'state': 'Mexico City', 'status': 'RECRUITING', 'country': 'Mexico', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+52 55 7586 4856'}], 'facility': 'Health Pharma Professional Research S.A. de C.V: ( Site 3301)', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '58260', 'city': 'Morelia', 'state': 'Michoacán', 'status': 'RECRUITING', 'country': 'Mexico', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+52 443 147 8545'}], 'facility': 'Centro de Investigacion Clinica Chapultepec ( Site 3309)', 'geoPoint': {'lat': 19.70078, 'lon': -101.18443}}, {'zip': '00918', 'city': 'San Juan', 'status': 'RECRUITING', 'country': 'Puerto Rico', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '7877582000'}], 'facility': 'Auxilio Mutuo Cancer Center ( Site 3900)', 'geoPoint': {'lat': 18.46633, 'lon': -66.10572}}, {'zip': '0181', 'city': 'Pretoria', 'state': 'Gauteng', 'status': 'RECRUITING', 'country': 'South Africa', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+27 12 993 2555'}], 'facility': 'Alberts Cellular Therapy. ( Site 4401)', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'zip': '7925', 'city': 'Cape Town', 'state': 'Western Cape', 'status': 'RECRUITING', 'country': 'South Africa', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+27727689024'}], 'facility': 'Groote Schuur Hospital ( Site 4400)', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '7580', 'city': 'Kuilsriver', 'state': 'Western Cape', 'status': 'RECRUITING', 'country': 'South Africa', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+27 21 900 6277'}], 'facility': 'Haemalife ( Site 4407)'}, {'zip': '08908', 'city': "L'Hospitalet Del Llobregat", 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+34932607750'}], 'facility': 'Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4601)'}, {'zip': '28223', 'city': 'Pozuelo de Alarcón', 'state': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '914521900'}], 'facility': 'HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 4602)', 'geoPoint': {'lat': 40.43293, 'lon': -3.81338}}, {'zip': '46010', 'city': 'Valencia', 'state': 'Valenciana, Comunitat', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '961973930'}], 'facility': 'HOSPITAL CLINICO DE VALENCIA-HEMATOLOGY ( Site 4603)', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '59100', 'city': 'Tekirdağ', 'state': 'Tekirdas', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '0090 282 250 50 50'}], 'facility': 'Namik Kemal University Medical Faculty-Hematology ( Site 4912)', 'geoPoint': {'lat': 40.9781, 'lon': 27.51101}}, {'zip': '06100', 'city': 'Ankara', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+90312 508 3508'}], 'facility': 'Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 4913)', 'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}, {'zip': '34214', 'city': 'Istanbul', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '0212 444 70 44'}], 'facility': 'Mega Medipol-Hematology ( Site 4904)', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34722', 'city': 'Istanbul', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '0090 216 606 52 00'}], 'facility': 'TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 4906)', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '35100', 'city': 'Izmir', 'status': 'RECRUITING', 'country': 'Turkey (Türkiye)', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+905325566128'}], 'facility': 'Ege Universitesi Hastanesi ( Site 4902)', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'zip': 'NG5 1PF', 'city': 'Nottingham', 'state': 'England', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+44115969116972549'}], 'facility': 'City Hospital, Nottingham University Hospitals-Hematology ( Site 5002)', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}, {'zip': 'NW1 2PG', 'city': 'London-Camden', 'state': 'London, City of', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Study Coordinator', 'role': 'CONTACT', 'phone': '+4420 3447 2528'}], 'facility': 'University College London Hospital-Cancer Clinical Trials Unit ( Site 5001)'}], 'centralContacts': [{'name': 'Toll Free Number', 'role': 'CONTACT', 'email': 'Trialsites@msd.com', 'phone': '1-888-577-8839'}], 'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Merck Sharp & Dohme LLC'}]}, 'ipdSharingStatementModule': {'url': 'https://externaldatasharing-msd.com/', 'ipdSharing': 'YES', 'description': 'https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}